The Class 2 recall pertains to the system's built-in shielding and collimation accessories. 

Leqembi (lecanemab) was approved by the FDA in 2023. It is an infusion drug that has been shown to reduce Alzheimer’s-related cognitive decline by up to 27%. 

Mastering the art of effective prompts has become a coveted skill in the fast-growing field of AI. 

The system was built with patients in mind, and its compact design has the potential to expand access to the modality where it may have previously been lacking. 

Chatbots may be able to accurately explain MRI results to patients in ways that radiologists are not routinely available to do. 

Gadoquatrane is now set to go through the regulatory review process on its trek to earning full FDA approval. 

Despite its high accuracy, CTA can come with tradeoffs including requiring radiologists to review a high number of images looking for findings that can be subtle, increasing case complexity and workloads. 

The pharmacy chain also agreed to perform an annual audit of billed drug prices to ensure it does not run afoul of the state’s “Most Favored Nation” policy. 

New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary.